HEALTH CARE:
PHARMACEUTICALS
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Immunomedics Inc. develops, manufactures and markets monoclonal antibody-based products for detection and treatment of cancer and other diseases. Focuses on therapeutic antibodies designed to carry radioisotopes, chemotherapeutic agents, toxins and other substances to a specific disease site or organ system.
| Market Cap | 2.218 Billion | Shares Outstanding | 152.02 Million | Avg Volume | 4.687 Million |
| 1-Yr BETA vs S&P TR | Current Ratio | 1.29 | Quick Ratio | 1.28 |
| Q1 2019 | All Institutions | Hedge Funds 1 |
|---|---|---|
| To trade IMMU now: | |
|
| Filers who had this stock in their top 10: | 11 | 7 (0.71%) |
| 13F Filers holding this stock: | 197 | 32 (3.26%) |
| Aggregate 13F shares on 03/31/2019: | 174.047 Million | 46.832 Million |
| Aggregate 13F shares on 12/31/2018: | 162.285 Million | 49.54 Million |
| Percent change: | 7.25% | -5.47% |
| Funds creating new positions: | 47 | 8 |
| Funds Adding to an existing position: | 71 | 11 |
| Funds closing out their position: | 50 | 12 |
| Funds reducing their position: | 53 | 8 |
| 1 hedge funds as identified by whalewisdom.com through public filings. | ||
View recent insider trading info
Immunomedics Inc. Chart by YCharts
Please sign in first
750 Thousand total shares from 3 transactions
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
67,467 | 2019-05-15 | 0 | |
|
|
0 | 2019-05-15 | 0 | |
|
115,987 | 2019-05-14 | 0 | |
|
18,468,310 | 2019-05-13 | 2 | |
|
FRICKER WILLIAM PRINCIPAL ACCOUNTING OFFICER |
|
0 | 2019-04-04 | 4 |
|
DELANEY BRENDAN CHIEF COMMERCIAL OFFICER |
|
0 | 2019-03-14 | 2 |
|
IANNONE ROBERT CHIEF MEDICAL OFFICER |
|
0 | 2019-03-14 | 2 |
|
MALIK USAMA CHIEF FINANCIAL & BUSINESS OFF |
|
0 | 2019-03-14 | 2 |
|
ROSENBERG MORRIS CHIEF TECHNOLOGY OFFICER |
|
0 | 2019-03-14 | 2 |
|
FREEDBERG JARED GENERAL COUNSEL |
|
0 | 2019-03-14 | 3 |
|
ANDREWS KURT J. CHIEF HUMAN RESOURCES OFFICER |
|
0 | 2019-03-14 | 2 |
|
0 | 2019-03-05 | 1 | |
|
BALL BRYAN CHIEF QUALITY OFFICER |
|
0 | 2019-03-05 | 2 |
|
0 | 2019-03-05 | 2 | |
|
BAUM CHARLES M PRESIDENT & CEO |
|
66,041 | 2019-02-25 | 2 |
|
PFREUNDSCHUH PETER P. CHIEF FINANCIAL OFFICER |
|
0 | 2019-01-26 | 0 |
|
FORRESTER ROBERT PRESIDENT AND CEO |
|
0 | 2019-01-03 | 0 |
|
3,924 | 2018-12-07 | 0 | |
|
PEHL MICHAEL F. PRESIDENT AND CEO |
|
0 | 2018-09-14 | 1 |
|
45,121 | 2018-06-21 | 0 | |
|
0 | 2018-06-08 | 0 | |
|
7,387,537 | 2018-02-28 | 0 | |
|
16,064,461 | 2017-11-14 | 1 | |
|
16,064,461 | 2017-11-14 | 2 | |
|
5,906,233 | 2017-08-31 | 0 | |
|
GARONE MICHAEL CHIEF FINANCIAL OFFICER |
|
0 | 2017-07-03 | 0 |
|
No longer subject to file | 2017-06-30 | 0 | |
|
0 | 2017-05-18 | 0 | |
|
0 | 2017-01-08 | 0 | |
|
78,325 | 2016-12-02 | 0 | |
|
No longer subject to file | 2015-12-01 | 0 | |
|
COLEMAN MORTON VICE PRESIDENT |
|
5,568,166 | 2014-02-21 | 0 |
|
No longer subject to file | 2013-12-04 | 0 | |
|
GORMAN GERARD G SVP, FIN. , AND CFO |
|
0 | 2013-08-16 | 0 |
|
6,667 | 2009-12-02 | 0 |
| Reporting Owners | Transaction Date | Transaction Code | Shares | Share Price | Acquired or Disposed | Shares Owned Following Transaction | Combined shares owned after filing | Direct/Indirect Ownership | 10b-5 |
|---|---|---|---|---|---|---|---|---|---|
|
AVORO CAPITAL ADVISORS LLC - Director SEE REMARKS see footnotes AGHAZADEH BEHZAD - Director SEE REMARKS see footnotes |
2019-05-15 | P | 125,000 | $14.95 | a | 18,464,461 | 18,468,310.00 | indirect | |
|
AVORO CAPITAL ADVISORS LLC - Director SEE REMARKS see footnotes AGHAZADEH BEHZAD - Director SEE REMARKS see footnotes |
2019-05-14 | P | 125,000 | $15.40 | a | 18,339,461 | 18,468,310.00 | indirect | |
|
AVORO CAPITAL ADVISORS LLC - Director SEE REMARKS see footnotes AGHAZADEH BEHZAD - Director SEE REMARKS see footnotes |
2019-05-13 | P | 500,000 | $15.07 | a | 18,214,461 | 18,468,310.00 | indirect | |
| 2019-04-04 | A | 15,000 | a | 15,000 | 0.00 | direct |
